ArriVent BioPharma, Inc. (AVBP) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-23

ArriVent BioPharma, Inc. (AVBP) has filed 4 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-23. 3 Form 8-K material event filings were reported by AVBP in the last 90 days. InsiderAlpha tracks every AVBP SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About ArriVent BioPharma, Inc. (AVBP)

SEC CIK	0001868279

90-Day SEC Filing Activity

Form 4 filings (90d)	4
Form 8-K filings (90d)	3
Latest Form 4 filing	2026-06-23

Recent AVBP Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2025-12-10	HILLHOUSE INVESTMENT MANAGEMENT, LTD.	10% Owner	S — Open-market sale	555.6K	$23.37	$12.98M	SEC
2025-07-11	LaChapelle Robin	Chief Operating Officer	M — Option exercise	2.0K	$2.28	$5K	SEC
2025-07-11	LaChapelle Robin	Chief Operating Officer	M — Option exercise	2.6K	$2.28	$6K	SEC
2025-07-11	LaChapelle Robin	Chief Operating Officer	M — Option exercise	6.5K	$2.28	$15K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for ArriVent BioPharma, Inc. (AVBP). Updated in real time as new filings are submitted to the SEC.

Most-Active AVBP Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Nolet Chris	1	—
Hohneker John	1	—
Parsey Merdad	1	—
Peterson Kristine	1	—

Recent AVBP Form 8-K Material Events

2026-06-22 — Item 5.07 [SEC]
2026-05-11 — Item 8.01, 9.01 [SEC]
2026-05-11 — Item 2.02, 9.01 [SEC]
2026-03-17 — Item 7.01, 8.01, 9.01 · Clinical · neutral [SEC]
ArriVent BioPharma announced it will present two preclinical posters at the 2026 AACR Annual Meeting, including data on the EGFR inhibitor firmonertinib and the dual-target MUC16/NaPi2b tetravalent ADC ARR-002. This is a routine conference presentation announcement with preclinic
2026-03-05 — Item 2.02, 9.01 · Earnings · neutral [SEC]
ArriVent BioPharma announced its financial results for Q4 2025 and full year 2025 on March 5, 2026. The filing provides standard results of operations and financial condition disclosure without indicating whether results beat or missed expectations.

Recent Insider Filings

2026-06-23 — Parsey Merdad (Director)
2026-06-23 — Peterson Kristine (Director)
2026-06-23 — Hohneker John (Director)
2026-06-23 — Nolet Chris (Director)
2026-02-05 — LaChapelle Robin (Chief Operating Officer)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in AVBP insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

AVBP Insider Trading — FAQ

What is the latest insider trade for AVBP?: ArriVent BioPharma, Inc. (AVBP) had 4 insider filings in the last 90 days, with the most recent on 2026-06-23. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying AVBP stock?: 0 insider purchases of AVBP were filed in the last 90 days.
How many insiders are selling AVBP stock?: 0 insider sales of AVBP were filed in the last 90 days.
Where can I see AVBP SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every AVBP SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live AVBP dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.